Bortezomib is a first-in-class, small-molecule proteasome inhibitor and a cornerstone therapeutic agent in oncology. It is a modified dipeptidyl boronic acid, synthetically designed to specifically and reversibly inhibit the chymotrypsin-like activity of the 26S proteasome complex. Its discovery and development stemmed from research into the ubiquitin-proteasome pathway as a novel target for cancer therapy, recognizing that malignant cells are particularly dependent on this system for protein homeostasis and survival signaling. Bortezomib (marketed as Velcade) gained FDA approval in 2003 for the treatment of multiple myeloma, representing a paradigm shift in the management of this disease and validating the proteasome as a viable therapeutic target. Its significance extends beyond myeloma, with applications in other hematologic malignancies and ongoing research in solid tumors, making it a prototypical agent in the class of proteasome inhibitors.
Quick Facts
| Also Known As | PS-341, Velcade, LDP-341, MG-341 |
|---|---|
| Sequence | Pyrazinecarbonyl-Phe-boroLeu (N/A - not a standard peptide sequence; it is a modified dipeptide boronic acid) |
| Molecular Formula | C19H25BN4O4 |
| Molecular Weight | 384.2 Da |
| PubChem CID | 387447 |
Research Parameters
| Half-Life | ~9-15 hours (after intravenous administration) |
|---|---|
| Stability | Lyophilized powder is stable under recommended storage conditions. After reconstitution with normal saline, the solution is stable for up to 8 hours at 25°C or when refrigerated at 2-8°C. The FDA-approved product labeling should be consulted for specific stability data. |
| Solubility | Normal Saline (0.9% Sodium Chloride Injection, USP) is the standard diluent for clinical intravenous or subcutaneous administration. |
| Storage (Lyophilized) | Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Protect from light. |
| Storage (Reconstituted) | Store reconstituted solution at 25°C (77°F) or refrigerated at 2-8°C (36-46°F). Use within 8 hours. Protect from light. |
| Typical Research Dose | Clinical dose is 1.3 mg/m² per administration, which translates to a variable absolute dose typically in the range of 2000-3000 mcg (2-3 mg) for an average adult. |
| Cycle Parameters | In clinical practice, a common cycle is 21 days, with doses administered on days 1, 4, 8, and 11, followed by a 10-day rest period (days 12-21). Treatment continues for multiple cycles based on response and tolerability. |
| Amino Acid Count | 4 |
Mechanism of Action
Bortezomib's primary mechanism of action is the potent, selective, and reversible inhibition of the 26S proteasome, a large protein complex responsible for the degradation of ubiquitin-tagged intracellular proteins. This inhibition disrupts multiple critical cellular pathways, leading to apoptosis in malignant cells.
Proteasome Inhibition: Bortezomib binds reversibly to the β5 subunit of the 20S core particle within the 26S proteasome, specifically inhibiting its chymotrypsin-like activity. This blockade prevents the degradation of polyubiquitinated proteins, leading to their accumulation within the cell.
Endoplasmic Reticulum Stress and Unfolded Protein Response (UPR): The accumulation of misfolded and regulatory proteins, particularly in secretory cells like plasma cells, induces severe endoplasmic reticulum (ER) stress. This activates the UPR, which, if prolonged and unresolved, switches from a pro-survival to a pro-apoptotic signal.
NF-κB Pathway Inhibition: The proteasome is required for the degradation of the inhibitory protein IκB, which sequesters the transcription factor NF-κB in the cytoplasm. By preventing IκB degradation, bortezomib inhibits NF-κB activation. Since NF-κB promotes cell survival, proliferation, and drug resistance, its inhibition contributes to apoptosis and chemosensitization.
Cell Cycle Arrest: Accumulation of cyclin-dependent kinase inhibitors (e.g., p21, p27) and other cell cycle regulators due to inhibited degradation leads to cell cycle arrest, primarily at the G2-M phase, preventing proliferation.
Activation of Intrinsic Apoptotic Pathway: The collective cellular stress from proteasome inhibition leads to mitochondrial outer membrane permeabilization, cytochrome c release, and activation of caspase-9 and the executioner caspase-3, culminating in programmed cell death.
Research Applications
Oncology (Multiple Myeloma and Lymphoma): Bortezomib is a first-line therapy for multiple myeloma, both in newly diagnosed and relapsed/refractory settings. It induces apoptosis in malignant plasma cells, inhibits bone marrow stromal cell support, and reduces bone resorption. In mantle cell lymphoma, it is also an approved therapeutic option.
Solid Tumor Research: Preclinical and clinical studies have investigated bortezomib in various solid tumors, including prostate, lung, and pancreatic cancers. Research focuses on its ability to sensitize tumor cells to chemotherapy and radiation by inhibiting NF-κB-mediated survival pathways.
Autoimmune and Inflammatory Diseases: Research explores bortezomib's potential in antibody-mediated diseases. By targeting plasma cells, it can deplete pathogenic antibody-producing cells, showing promise in models of antibody-mediated rejection in transplantation and autoimmune disorders like lupus and autoimmune hemolytic anemia.
Antifungal Research: Interestingly, due to the essential nature of the proteasome in some fungi (e.g., Cryptococcus), bortezomib and its analogs are being investigated for their antifungal properties, representing a novel antimicrobial strategy.
Safety & Side Effects
The safety profile is well-characterized from extensive clinical use. Common side effects include peripheral sensory neuropathy (often dose-limiting), fatigue, thrombocytopenia, neutropenia, anemia, nausea, diarrhea, and constipation. A significant but manageable side effect is herpes zoster reactivation, necessitating antiviral prophylaxis. Less common but serious risks include progressive multifocal leukoencephalopathy (PML), acute lung injury, and tumor lysis syndrome. Theoretical concerns exist regarding cardiac effects and liver toxicity. Peripheral neuropathy is often reversible upon dose reduction or discontinuation. Animal toxicology studies showed corresponding hematological, gastrointestinal, and neurological effects.
Dosage Information
This information is derived from clinical use and should not be interpreted as research dosing guidance. In clinical oncology, bortezomib is administered under strict medical supervision. The typical regimen for multiple myeloma involves intravenous or subcutaneous injection at a dose of 1.3 mg/m². It is commonly given twice weekly (e.g., days 1, 4, 8, and 11) during a 21-day treatment cycle, followed by a 10-day rest period. Subcutaneous administration has become preferred due to a improved safety profile regarding peripheral neuropathy. Treatment duration varies based on the treatment line, combination regimen, and patient response.
References
Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research. 1999;59(11):2615-2622.
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine. 2003;348(26):2609-2617.
Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clinical Cancer Research. 2007;13(18 Pt 1):5291-5294.
Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences. 2002;99(22):14374-14379.
Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 2011;12(5):431-440.
Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clinical Cancer Research. 2003;9(17):6316-6325.